与阿尔茨海默病相关的β-粉样蛋白和免疫反应
Elizaveta Kolobova1,2, Irina Petrushanko1, Vladimir Mitkevich1
1Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.
Cells
|October 15, 2024
概括
阿尔茨海默病涉及β-粉样蛋白 (Aβs) 和脑斑. 本综述探讨了Aβ与免疫系统的相互作用,重点关注B细胞在阿尔茨海默氏症病原发生中的作用.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 的特点是大脑中β-粉样蛋白 (Aβ) 积累和斑块形成.
- 不同的Aβ结构形式和异型表现出不同的寡合化,毒性和对AD发展的影响.
- Aβs与先天性和适应性免疫系统相互作用,可能调节AD的发病和进展.
研究的目的:
- 审查当前对beta-amyloids与阿尔茨海默病免疫反应之间的相互作用的理解.
- 专门研究B细胞在AD病变发生过程中的潜在作用.
主要方法:
- 对Aβs,免疫系统相互作用和阿尔茨海默病现有研究的文献综述.
- 对专注于B细胞参与AD病理学的研究的分析.
主要成果:
- β-粉样蛋白及其各种形式是AD病变的核心.
- 在Aβs和先天性和适应性免疫之间存在复杂的相互作用.
- 新出现的证据表明,B细胞在AD中起着重要作用.
结论:
- Aβs与免疫系统之间的复杂关系对于理解AD至关重要.
- B细胞是未来AD研究和治疗策略的重点领域.
更多相关视频
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
9.3K
09:31Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
Published on: March 7, 2019
10.6K
相关概念视频
Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K
Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
Alzheimer's Disease: Treatment
166
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
166
